Global CINV Existing and Pipeline Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global CINV Existing and Pipeline Drugs market size was valued at USD 1562.2 million in 2023 and is forecast to a readjusted size of USD 1929.5 million by 2030 with a CAGR of 3.1% during review period.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the CINV Existing and Pipeline Drugs industry chain, the market status of Hospitals (Aloxi, Zofran Generic), Specialty Clinics (Aloxi, Zofran Generic), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of CINV Existing and Pipeline Drugs.
Regionally, the report analyzes the CINV Existing and Pipeline Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global CINV Existing and Pipeline Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the CINV Existing and Pipeline Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the CINV Existing and Pipeline Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Kg), revenue generated, and market share of different by Type (e.g., Aloxi, Zofran Generic).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the CINV Existing and Pipeline Drugs market.
Regional Analysis: The report involves examining the CINV Existing and Pipeline Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the CINV Existing and Pipeline Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to CINV Existing and Pipeline Drugs:
Company Analysis: Report covers individual CINV Existing and Pipeline Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards CINV Existing and Pipeline Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Specialty Clinics).
Technology Analysis: Report covers specific technologies relevant to CINV Existing and Pipeline Drugs. It assesses the current state, advancements, and potential future developments in CINV Existing and Pipeline Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the CINV Existing and Pipeline Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
CINV Existing and Pipeline Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe CINV Existing and Pipeline Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of CINV Existing and Pipeline Drugs, with price, sales, revenue and global market share of CINV Existing and Pipeline Drugs from 2019 to 2024.
Chapter 3, the CINV Existing and Pipeline Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CINV Existing and Pipeline Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of CINV Existing and Pipeline Drugs.
Chapter 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, customers, research findings and conclusion.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the CINV Existing and Pipeline Drugs industry chain, the market status of Hospitals (Aloxi, Zofran Generic), Specialty Clinics (Aloxi, Zofran Generic), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of CINV Existing and Pipeline Drugs.
Regionally, the report analyzes the CINV Existing and Pipeline Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global CINV Existing and Pipeline Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the CINV Existing and Pipeline Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the CINV Existing and Pipeline Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Kg), revenue generated, and market share of different by Type (e.g., Aloxi, Zofran Generic).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the CINV Existing and Pipeline Drugs market.
Regional Analysis: The report involves examining the CINV Existing and Pipeline Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the CINV Existing and Pipeline Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to CINV Existing and Pipeline Drugs:
Company Analysis: Report covers individual CINV Existing and Pipeline Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards CINV Existing and Pipeline Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Specialty Clinics).
Technology Analysis: Report covers specific technologies relevant to CINV Existing and Pipeline Drugs. It assesses the current state, advancements, and potential future developments in CINV Existing and Pipeline Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the CINV Existing and Pipeline Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
CINV Existing and Pipeline Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Aloxi
- Zofran Generic
- Kytril Generic
- Emend
- Akynzeo
- SUSTOL
- Rolapitant
- Hospitals
- Specialty Clinics
- Diagnostic Centers Therapeutics
- Hospital Pharmacies
- Drugstores
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe CINV Existing and Pipeline Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of CINV Existing and Pipeline Drugs, with price, sales, revenue and global market share of CINV Existing and Pipeline Drugs from 2019 to 2024.
Chapter 3, the CINV Existing and Pipeline Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CINV Existing and Pipeline Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of CINV Existing and Pipeline Drugs.
Chapter 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of CINV Existing and Pipeline Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Aloxi
1.3.3 Zofran Generic
1.3.4 Kytril Generic
1.3.5 Emend
1.3.6 Akynzeo
1.3.7 SUSTOL
1.3.8 Rolapitant
1.4 Market Analysis by Application
1.4.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Specialty Clinics
1.4.4 Diagnostic Centers Therapeutics
1.4.5 Hospital Pharmacies
1.4.6 Drugstores
1.5 Global CINV Existing and Pipeline Drugs Market Size & Forecast
1.5.1 Global CINV Existing and Pipeline Drugs Consumption Value (2019 & 2023 & 2030)
1.5.2 Global CINV Existing and Pipeline Drugs Sales Quantity (2019-2030)
1.5.3 Global CINV Existing and Pipeline Drugs Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
2.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 GlaxoSmithKline Recent Developments/Updates
2.2 Helsinn
2.2.1 Helsinn Details
2.2.2 Helsinn Major Business
2.2.3 Helsinn CINV Existing and Pipeline Drugs Product and Services
2.2.4 Helsinn CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Helsinn Recent Developments/Updates
2.3 Heron Therapeutics
2.3.1 Heron Therapeutics Details
2.3.2 Heron Therapeutics Major Business
2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
2.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Heron Therapeutics Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck CINV Existing and Pipeline Drugs Product and Services
2.4.4 Merck CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Merck Recent Developments/Updates
2.5 Tesaro
2.5.1 Tesaro Details
2.5.2 Tesaro Major Business
2.5.3 Tesaro CINV Existing and Pipeline Drugs Product and Services
2.5.4 Tesaro CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Tesaro Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CINV EXISTING AND PIPELINE DRUGS BY MANUFACTURER
3.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturer (2019-2024)
3.2 Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2019-2024)
3.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of CINV Existing and Pipeline Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2023
3.4.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2023
3.5 CINV Existing and Pipeline Drugs Market: Overall Company Footprint Analysis
3.5.1 CINV Existing and Pipeline Drugs Market: Region Footprint
3.5.2 CINV Existing and Pipeline Drugs Market: Company Product Type Footprint
3.5.3 CINV Existing and Pipeline Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global CINV Existing and Pipeline Drugs Market Size by Region
4.1.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
4.1.2 Global CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
4.1.3 Global CINV Existing and Pipeline Drugs Average Price by Region (2019-2030)
4.2 North America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.3 Europe CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.4 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.5 South America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.6 Middle East and Africa CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
5.2 Global CINV Existing and Pipeline Drugs Consumption Value by Type (2019-2030)
5.3 Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
6.2 Global CINV Existing and Pipeline Drugs Consumption Value by Application (2019-2030)
6.3 Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
7.2 North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
7.3 North America CINV Existing and Pipeline Drugs Market Size by Country
7.3.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
7.3.2 North America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
8.2 Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
8.3 Europe CINV Existing and Pipeline Drugs Market Size by Country
8.3.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
8.3.2 Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Region
9.3.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
10.2 South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
10.3 South America CINV Existing and Pipeline Drugs Market Size by Country
10.3.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
10.3.2 South America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa CINV Existing and Pipeline Drugs Market Size by Country
11.3.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 CINV Existing and Pipeline Drugs Market Drivers
12.2 CINV Existing and Pipeline Drugs Market Restraints
12.3 CINV Existing and Pipeline Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of CINV Existing and Pipeline Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of CINV Existing and Pipeline Drugs
13.3 CINV Existing and Pipeline Drugs Production Process
13.4 CINV Existing and Pipeline Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 CINV Existing and Pipeline Drugs Typical Distributors
14.3 CINV Existing and Pipeline Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of CINV Existing and Pipeline Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Aloxi
1.3.3 Zofran Generic
1.3.4 Kytril Generic
1.3.5 Emend
1.3.6 Akynzeo
1.3.7 SUSTOL
1.3.8 Rolapitant
1.4 Market Analysis by Application
1.4.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Specialty Clinics
1.4.4 Diagnostic Centers Therapeutics
1.4.5 Hospital Pharmacies
1.4.6 Drugstores
1.5 Global CINV Existing and Pipeline Drugs Market Size & Forecast
1.5.1 Global CINV Existing and Pipeline Drugs Consumption Value (2019 & 2023 & 2030)
1.5.2 Global CINV Existing and Pipeline Drugs Sales Quantity (2019-2030)
1.5.3 Global CINV Existing and Pipeline Drugs Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
2.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 GlaxoSmithKline Recent Developments/Updates
2.2 Helsinn
2.2.1 Helsinn Details
2.2.2 Helsinn Major Business
2.2.3 Helsinn CINV Existing and Pipeline Drugs Product and Services
2.2.4 Helsinn CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Helsinn Recent Developments/Updates
2.3 Heron Therapeutics
2.3.1 Heron Therapeutics Details
2.3.2 Heron Therapeutics Major Business
2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
2.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Heron Therapeutics Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck CINV Existing and Pipeline Drugs Product and Services
2.4.4 Merck CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Merck Recent Developments/Updates
2.5 Tesaro
2.5.1 Tesaro Details
2.5.2 Tesaro Major Business
2.5.3 Tesaro CINV Existing and Pipeline Drugs Product and Services
2.5.4 Tesaro CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Tesaro Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CINV EXISTING AND PIPELINE DRUGS BY MANUFACTURER
3.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturer (2019-2024)
3.2 Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2019-2024)
3.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of CINV Existing and Pipeline Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2023
3.4.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2023
3.5 CINV Existing and Pipeline Drugs Market: Overall Company Footprint Analysis
3.5.1 CINV Existing and Pipeline Drugs Market: Region Footprint
3.5.2 CINV Existing and Pipeline Drugs Market: Company Product Type Footprint
3.5.3 CINV Existing and Pipeline Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global CINV Existing and Pipeline Drugs Market Size by Region
4.1.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
4.1.2 Global CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
4.1.3 Global CINV Existing and Pipeline Drugs Average Price by Region (2019-2030)
4.2 North America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.3 Europe CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.4 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.5 South America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.6 Middle East and Africa CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
5.2 Global CINV Existing and Pipeline Drugs Consumption Value by Type (2019-2030)
5.3 Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
6.2 Global CINV Existing and Pipeline Drugs Consumption Value by Application (2019-2030)
6.3 Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
7.2 North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
7.3 North America CINV Existing and Pipeline Drugs Market Size by Country
7.3.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
7.3.2 North America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
8.2 Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
8.3 Europe CINV Existing and Pipeline Drugs Market Size by Country
8.3.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
8.3.2 Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Region
9.3.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
10.2 South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
10.3 South America CINV Existing and Pipeline Drugs Market Size by Country
10.3.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
10.3.2 South America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa CINV Existing and Pipeline Drugs Market Size by Country
11.3.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 CINV Existing and Pipeline Drugs Market Drivers
12.2 CINV Existing and Pipeline Drugs Market Restraints
12.3 CINV Existing and Pipeline Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of CINV Existing and Pipeline Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of CINV Existing and Pipeline Drugs
13.3 CINV Existing and Pipeline Drugs Production Process
13.4 CINV Existing and Pipeline Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 CINV Existing and Pipeline Drugs Typical Distributors
14.3 CINV Existing and Pipeline Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global CINV Existing and Pipeline Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global CINV Existing and Pipeline Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 4. GlaxoSmithKline Major Business
Table 5. GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
Table 6. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. GlaxoSmithKline Recent Developments/Updates
Table 8. Helsinn Basic Information, Manufacturing Base and Competitors
Table 9. Helsinn Major Business
Table 10. Helsinn CINV Existing and Pipeline Drugs Product and Services
Table 11. Helsinn CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Helsinn Recent Developments/Updates
Table 13. Heron Therapeutics Basic Information, Manufacturing Base and Competitors
Table 14. Heron Therapeutics Major Business
Table 15. Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
Table 16. Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Heron Therapeutics Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck CINV Existing and Pipeline Drugs Product and Services
Table 21. Merck CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Merck Recent Developments/Updates
Table 23. Tesaro Basic Information, Manufacturing Base and Competitors
Table 24. Tesaro Major Business
Table 25. Tesaro CINV Existing and Pipeline Drugs Product and Services
Table 26. Tesaro CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Tesaro Recent Developments/Updates
Table 28. Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturer (2019-2024) & (Kg)
Table 29. Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
Table 30. Global CINV Existing and Pipeline Drugs Average Price by Manufacturer (2019-2024) & (USD/Kg)
Table 31. Market Position of Manufacturers in CINV Existing and Pipeline Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 32. Head Office and CINV Existing and Pipeline Drugs Production Site of Key Manufacturer
Table 33. CINV Existing and Pipeline Drugs Market: Company Product Type Footprint
Table 34. CINV Existing and Pipeline Drugs Market: Company Product Application Footprint
Table 35. CINV Existing and Pipeline Drugs New Market Entrants and Barriers to Market Entry
Table 36. CINV Existing and Pipeline Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 37. Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 38. Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 39. Global CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 40. Global CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 41. Global CINV Existing and Pipeline Drugs Average Price by Region (2019-2024) & (USD/Kg)
Table 42. Global CINV Existing and Pipeline Drugs Average Price by Region (2025-2030) & (USD/Kg)
Table 43. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 44. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 45. Global CINV Existing and Pipeline Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 46. Global CINV Existing and Pipeline Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 47. Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2024) & (USD/Kg)
Table 48. Global CINV Existing and Pipeline Drugs Average Price by Type (2025-2030) & (USD/Kg)
Table 49. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 50. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 51. Global CINV Existing and Pipeline Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 52. Global CINV Existing and Pipeline Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 53. Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2024) & (USD/Kg)
Table 54. Global CINV Existing and Pipeline Drugs Average Price by Application (2025-2030) & (USD/Kg)
Table 55. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 56. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 57. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 58. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 59. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 60. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 61. North America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 62. North America CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 63. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 64. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 65. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 66. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 67. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 68. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 69. Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 70. Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 71. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 72. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 73. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 74. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 75. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 76. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 77. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 78. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 79. South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 80. South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 81. South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 82. South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 83. South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 84. South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 85. South America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 86. South America CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 87. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 88. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 89. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 90. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 91. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 92. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 93. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 94. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 95. CINV Existing and Pipeline Drugs Raw Material
Table 96. Key Manufacturers of CINV Existing and Pipeline Drugs Raw Materials
Table 97. CINV Existing and Pipeline Drugs Typical Distributors
Table 98. CINV Existing and Pipeline Drugs Typical Customers
Table 1. Global CINV Existing and Pipeline Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global CINV Existing and Pipeline Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 4. GlaxoSmithKline Major Business
Table 5. GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
Table 6. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. GlaxoSmithKline Recent Developments/Updates
Table 8. Helsinn Basic Information, Manufacturing Base and Competitors
Table 9. Helsinn Major Business
Table 10. Helsinn CINV Existing and Pipeline Drugs Product and Services
Table 11. Helsinn CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Helsinn Recent Developments/Updates
Table 13. Heron Therapeutics Basic Information, Manufacturing Base and Competitors
Table 14. Heron Therapeutics Major Business
Table 15. Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
Table 16. Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Heron Therapeutics Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck CINV Existing and Pipeline Drugs Product and Services
Table 21. Merck CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Merck Recent Developments/Updates
Table 23. Tesaro Basic Information, Manufacturing Base and Competitors
Table 24. Tesaro Major Business
Table 25. Tesaro CINV Existing and Pipeline Drugs Product and Services
Table 26. Tesaro CINV Existing and Pipeline Drugs Sales Quantity (Kg), Average Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Tesaro Recent Developments/Updates
Table 28. Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturer (2019-2024) & (Kg)
Table 29. Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
Table 30. Global CINV Existing and Pipeline Drugs Average Price by Manufacturer (2019-2024) & (USD/Kg)
Table 31. Market Position of Manufacturers in CINV Existing and Pipeline Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 32. Head Office and CINV Existing and Pipeline Drugs Production Site of Key Manufacturer
Table 33. CINV Existing and Pipeline Drugs Market: Company Product Type Footprint
Table 34. CINV Existing and Pipeline Drugs Market: Company Product Application Footprint
Table 35. CINV Existing and Pipeline Drugs New Market Entrants and Barriers to Market Entry
Table 36. CINV Existing and Pipeline Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 37. Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 38. Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 39. Global CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 40. Global CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 41. Global CINV Existing and Pipeline Drugs Average Price by Region (2019-2024) & (USD/Kg)
Table 42. Global CINV Existing and Pipeline Drugs Average Price by Region (2025-2030) & (USD/Kg)
Table 43. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 44. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 45. Global CINV Existing and Pipeline Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 46. Global CINV Existing and Pipeline Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 47. Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2024) & (USD/Kg)
Table 48. Global CINV Existing and Pipeline Drugs Average Price by Type (2025-2030) & (USD/Kg)
Table 49. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 50. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 51. Global CINV Existing and Pipeline Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 52. Global CINV Existing and Pipeline Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 53. Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2024) & (USD/Kg)
Table 54. Global CINV Existing and Pipeline Drugs Average Price by Application (2025-2030) & (USD/Kg)
Table 55. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 56. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 57. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 58. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 59. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 60. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 61. North America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 62. North America CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 63. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 64. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 65. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 66. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 67. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 68. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 69. Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 70. Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 71. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 72. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 73. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 74. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 75. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 76. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 77. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 78. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 79. South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 80. South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 81. South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 82. South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 83. South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2024) & (Kg)
Table 84. South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2025-2030) & (Kg)
Table 85. South America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 86. South America CINV Existing and Pipeline Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 87. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2024) & (Kg)
Table 88. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2025-2030) & (Kg)
Table 89. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2024) & (Kg)
Table 90. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2025-2030) & (Kg)
Table 91. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2024) & (Kg)
Table 92. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Region (2025-2030) & (Kg)
Table 93. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 94. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 95. CINV Existing and Pipeline Drugs Raw Material
Table 96. Key Manufacturers of CINV Existing and Pipeline Drugs Raw Materials
Table 97. CINV Existing and Pipeline Drugs Typical Distributors
Table 98. CINV Existing and Pipeline Drugs Typical Customers
LIST OF FIGURES
Figure 1. CINV Existing and Pipeline Drugs Picture
Figure 2. Global CINV Existing and Pipeline Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Type in 2023
Figure 4. Aloxi Examples
Figure 5. Zofran Generic Examples
Figure 6. Kytril Generic Examples
Figure 7. Emend Examples
Figure 8. Akynzeo Examples
Figure 9. SUSTOL Examples
Figure 10. Rolapitant Examples
Figure 11. Global CINV Existing and Pipeline Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 12. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Application in 2023
Figure 13. Hospitals Examples
Figure 14. Specialty Clinics Examples
Figure 15. Diagnostic Centers Therapeutics Examples
Figure 16. Hospital Pharmacies Examples
Figure 17. Drugstores Examples
Figure 18. Global CINV Existing and Pipeline Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 19. Global CINV Existing and Pipeline Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 20. Global CINV Existing and Pipeline Drugs Sales Quantity (2019-2030) & (Kg)
Figure 21. Global CINV Existing and Pipeline Drugs Average Price (2019-2030) & (USD/Kg)
Figure 22. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Manufacturer in 2023
Figure 23. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Manufacturer in 2023
Figure 24. Producer Shipments of CINV Existing and Pipeline Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 25. Top 3 CINV Existing and Pipeline Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 26. Top 6 CINV Existing and Pipeline Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 27. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 28. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 29. North America CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 30. Europe CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 31. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 32. South America CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 33. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 34. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 35. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Type (2019-2030)
Figure 36. Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2030) & (USD/Kg)
Figure 37. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 38. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Application (2019-2030)
Figure 39. Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2030) & (USD/Kg)
Figure 40. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 41. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 42. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 43. North America CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 44. United States CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. Canada CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. Mexico CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 48. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 49. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 50. Europe CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 51. Germany CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. France CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. United Kingdom CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Russia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Italy CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 57. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 58. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 59. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 60. China CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Japan CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Korea CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. India CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Southeast Asia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Australia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 67. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 68. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 69. South America CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 70. Brazil CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Argentina CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 73. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 74. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 75. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 76. Turkey CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Egypt CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 78. Saudi Arabia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 79. South Africa CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 80. CINV Existing and Pipeline Drugs Market Drivers
Figure 81. CINV Existing and Pipeline Drugs Market Restraints
Figure 82. CINV Existing and Pipeline Drugs Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs in 2023
Figure 85. Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
Figure 86. CINV Existing and Pipeline Drugs Industrial Chain
Figure 87. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 88. Direct Channel Pros & Cons
Figure 89. Indirect Channel Pros & Cons
Figure 90. Methodology
Figure 91. Research Process and Data Source
Figure 1. CINV Existing and Pipeline Drugs Picture
Figure 2. Global CINV Existing and Pipeline Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Type in 2023
Figure 4. Aloxi Examples
Figure 5. Zofran Generic Examples
Figure 6. Kytril Generic Examples
Figure 7. Emend Examples
Figure 8. Akynzeo Examples
Figure 9. SUSTOL Examples
Figure 10. Rolapitant Examples
Figure 11. Global CINV Existing and Pipeline Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 12. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Application in 2023
Figure 13. Hospitals Examples
Figure 14. Specialty Clinics Examples
Figure 15. Diagnostic Centers Therapeutics Examples
Figure 16. Hospital Pharmacies Examples
Figure 17. Drugstores Examples
Figure 18. Global CINV Existing and Pipeline Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 19. Global CINV Existing and Pipeline Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 20. Global CINV Existing and Pipeline Drugs Sales Quantity (2019-2030) & (Kg)
Figure 21. Global CINV Existing and Pipeline Drugs Average Price (2019-2030) & (USD/Kg)
Figure 22. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Manufacturer in 2023
Figure 23. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Manufacturer in 2023
Figure 24. Producer Shipments of CINV Existing and Pipeline Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 25. Top 3 CINV Existing and Pipeline Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 26. Top 6 CINV Existing and Pipeline Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 27. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 28. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 29. North America CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 30. Europe CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 31. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 32. South America CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 33. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value (2019-2030) & (USD Million)
Figure 34. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 35. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Type (2019-2030)
Figure 36. Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2030) & (USD/Kg)
Figure 37. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 38. Global CINV Existing and Pipeline Drugs Consumption Value Market Share by Application (2019-2030)
Figure 39. Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2030) & (USD/Kg)
Figure 40. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 41. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 42. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 43. North America CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 44. United States CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. Canada CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. Mexico CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 48. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 49. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 50. Europe CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 51. Germany CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. France CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. United Kingdom CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Russia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Italy CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 57. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 58. Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 59. Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 60. China CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Japan CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Korea CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. India CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Southeast Asia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Australia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 67. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 68. South America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 69. South America CINV Existing and Pipeline Drugs Consumption Value Market Share by Country (2019-2030)
Figure 70. Brazil CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Argentina CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 73. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 74. Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 75. Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value Market Share by Region (2019-2030)
Figure 76. Turkey CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Egypt CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 78. Saudi Arabia CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 79. South Africa CINV Existing and Pipeline Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 80. CINV Existing and Pipeline Drugs Market Drivers
Figure 81. CINV Existing and Pipeline Drugs Market Restraints
Figure 82. CINV Existing and Pipeline Drugs Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs in 2023
Figure 85. Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
Figure 86. CINV Existing and Pipeline Drugs Industrial Chain
Figure 87. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 88. Direct Channel Pros & Cons
Figure 89. Indirect Channel Pros & Cons
Figure 90. Methodology
Figure 91. Research Process and Data Source
